Table 1 Patient characteristics
Variable | All patients (n = 97) | Low polyhedrocytes group (n = 14) | High polyhedrocytes group (n = 83) | p-value |
|---|---|---|---|---|
Male sex, n (%) | 63 (64.95) | 11 (78.57) | 52 (62.65) | 0.37 |
Age, years | 67.49 ± 8.82 | 70.64 ± 10.98 | 66.96 ± 8.36 | 0.15 |
Current smoking, n (%) | 22 (22.68) | 4 (28.57) | 18 (21.69) | 0.73 |
BMI, kg/m2 | 30.5 (27.4–34.4) | 30.4 (28.1–35.7) | 30.6 (27.2–34.1) | 0.79 |
Hypertension, n (%) | 93 (95.88) | 13 (92.86) | 80 (96.39) | 0.47 |
Coronary artery disease, n (%) | 74 (76.29) | 11 (78.57) | 63 (75.90) | 1.00 |
T2D time since diagnosis, years | 9.30 (5.75–14.30) | 7.50 (5.25–15.00) | 9.45 (6.00–13.98) | 0.94 |
Drugs | ||||
Sulphonylurea, n (%) | 37 (38) | 7 (50) | 30 (36) | 0.38 |
Biguanide, n (%) | 61 (63) | 6 (43) | 55 (66) | 0.13 |
Insulin, n (%) | 25 (26) | 4 (29) | 21 (25) | 0.75 |
Beta-blocker, n (%) | 82 (85) | 12 (86) | 70 (84) | 1.00 |
ACEI, n (%) | 67 (69) | 12 (86) | 55 (66) | 0.21 |
Calcium antagonist, n (%) | 32 (33) | 3 (21) | 29 (35) | 0.38 |
Clopidogrel, n (%) | 22 (23) | 5 (36) | 17 (20) | 0.30 |
Aspirin, n (%) | 79 (81) | 13 (93) | 66 (80) | 0.46 |
Statin, n (%) | 80 (82) | 14 (100) | 66 (80) | 0.12 |
ARB, n (%) | 17 (18) | 2 (14) | 15 (18) | 1.00 |
Loop diuretic, n (%) | 30 (31) | 6 (43) | 24 (29) | 0.35 |
Spironolactone, n (%) | 22 (23) | 3 (21) | 19 (23) | 1.00 |